PAVmed (FRA:1P5) Cyclically Adjusted PB Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1P5 PAVmed Inc FRA:1P5
44 GF Score
Price €3.32
GF Value €1.01
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is PAVmed Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


PAVmed  (FRA:1P5) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


PAVmed Cyclically Adjusted PB Ratio Related Terms


PAVmed Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for PAVmed's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PAVmed Cyclically Adjusted PB Ratio Chart

PAVmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.36 1.29 -

PAVmed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.93 - - - -

FRA:1P5 vs ELUT, NSPR, SNWV: Cyclically Adjusted PB Ratio Comparison

For the Medical Devices subindustry, PAVmed's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PAVmed Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PAVmed's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where PAVmed's Cyclically Adjusted PB Ratio falls into.


FRA:1P5
44GF Score
PAVmed Inc FRA:1P5
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PAVmed Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

PAVmed's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, PAVmed's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.156/333.9520*333.9520
=2.156

Current CPI (Jun. 2026) = 333.9520.

PAVmed Quarterly Data

Book Value per Share CPI Adj_Book
201609 34.408 241.428 47.594
201612 -10.211 241.432 -14.124
201703 -136.166 243.801 -186.516
201706 -149.455 244.955 -203.755
201709 -174.097 246.819 -235.557
201712 -99.951 246.524 -135.398
201803 -30.497 249.554 -40.811
201806 69.999 251.989 92.767
201809 23.305 252.439 30.830
201812 -65.379 251.233 -86.905
201903 -114.433 254.202 -150.334
201906 -46.770 256.143 -60.977
201909 -52.335 256.759 -68.069
201912 -68.678 256.974 -89.251
202003 -172.377 258.115 -223.023
202006 -127.073 257.797 -164.611
202009 -133.109 260.280 -170.785
202012 -17.346 260.474 -22.239
202103 213.732 264.877 269.469
202106 181.700 271.696 223.334
202109 151.272 274.310 184.162
202112 352.784 278.802 422.568
202203 289.664 287.504 336.461
202206 192.161 296.311 216.572
202209 129.155 296.808 145.318
202212 36.757 296.797 41.358
202303 33.091 301.836 36.612
202306 -13.951 305.109 -15.270
202309 -66.555 307.789 -72.212
202312 -85.512 306.746 -93.096
202403 -74.146 312.332 -79.278
202406 -63.847 314.175 -67.866
202409 -31.819 315.301 -33.701
202412 -26.773 315.605 -28.329
202503 20.957 319.799 21.884
202506 4.554 322.561 4.715
202509 -1.706 324.800 -1.754
202512 -2.182 324.054 -2.249
202603 2.939 330.213 2.972
202606 2.156 333.952 2.156

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is PAVmed (FRA:1P5) Overvalued in 2026?

Based on GuruFocus' analysis, PAVmed stock appears to be overvalued. The current stock price of €3.32 is trading 228.7% above its estimated GF Value™ of €1.01. GuruFocus considers PAVmed to be Significantly Overvalued.

Key valuation signals for FRA:1P5:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €1.01 vs. price of €3.32 (228.7% above fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the FRA:1P5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PAVmed Business Description

Other Exchanges PAVM:USA
Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
44GF Score

Get the complete analysis for FRA:1P5

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.32
Price
€1.01
GF Value